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Nonalcoholic fatty liver disease 
and the risk of atrial fibrillation 
stratified by body mass index: 
a nationwide population‑based 
study
So‑Ryoung Lee1,5, Kyung‑Do Han2,5, Eue‑Keun Choi1*, Seil Oh1 & Gregory Y. H. Lip1,3,4
We evaluated the association between nonalcoholic fatty liver disease (NAFLD) and incident atrial 
fibrillation (AF) and analyzed the impact of NAFLD on AF risk in relation to body mass index (BMI). A 
total of 8,048,055 subjects without significant liver disease who were available fatty liver index (FLI) 
values were included. Subjects were categorized into 3 groups based on FLI: < 30, 30 to < 60, and ≥ 60. 
During a median 8‑year of follow‑up, 534,442 subjects were newly diagnosed as AF (8.27 per 1000 
person‑years). Higher FLI was associated with an increased risk of AF (hazard ratio [HR] 1.053, 95% 
confidence interval [CI] 1.046–1.060 in 30 ≤ FLI < 60, and HR 1.115, 95% CI 1.106–1.125 in FLI ≥ 60). In 
underweight subjects (BMI < 18.5 kg/m2), higher FLI raised the risk of AF (by 1.6‑fold in 30 ≤ FLI < 60 
and by twofold in FLI ≥ 60). In normal‑ and overweight subjects, higher FLI was associated with an 
increased risk of AF, but the HRs were attenuated. In obese subjects, higher FLI was not associated 
with higher risk of AF. NAFLD as assessed by FLI was independently associated with an increased risk 
of AF in nonobese subjects with BMI < 25 kg/m2. The impact of NAFLD on AF risk was accentuated in 
lean subjects with underweight.
Nonalcoholic fatty liver disease (NAFLD) is known as predominant macrovesicular steatosis of the  liver1. NAFLD 
frequently coexists with comorbidities such as obesity, insulin resistance, hypertension, and dyslipidemia, which 
are risk factors for cardiovascular disease. Thus, NAFLD can be considered as the hepatic manifestation of meta-
bolic  syndrome2. The association between NAFLD and cardiovascular diseases has been reported for coronary 
artery disease, cardiomyopathy and cardiac  arrhythmias3–5.
Atrial fibrillation (AF) is the most common cause of sustained cardiac arrhythmia, and the link between 
NAFLD and incident AF has been highlighted in recent years. Although several epidemiologic studies have 
suggested an association between NAFLD and the risk of AF, the results are somewhat conflicting, especially 
based on characteristics of the study  population6–9.
Nonetheless, the prevalence of NAFLD has increased worldwide with the rising trend of sedentary lifestyle 
and the increasing rate of obesity. Currently, the global prevalence of NAFLD is reported to be more than 25%2,10. 
The prevalence of NAFLD in Asians is also increasing, and is reported to be 10 to 30%10. Despite the strong 
association between NAFLD and obesity, NAFLD is also seen in the nonobese population, and nonobese or 
lean NAFLD is more common in the Asian  population11–15. There is limited data about the association between 
NAFLD and incident AF in the Asian population, who have a distinctively higher prevalence of nonobese 
NAFLD.
In this study, we evaluated the association between NAFLD as assessed by the fatty liver index (FLI) and 
incident AF in a large-scale observational cohort comprising the Asian population. In addition, we analyzed the 
impact of NAFLD on the risk of AF in relation to the body mass index (BMI).
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Methods
Data sources. This study was based on the data from the Korean National Health Insurance Service (NHIS) 
database from 2009 to 2017. The Korean NHIS is a single insurer and a mandatory health insurance program 
that provides comprehensive medical care coverage for 97% of the Korean population managed by the Korean 
government. The Medical Aid program covers the remaining 3% of the population with low income. Informa-
tion on Medical Aid beneficiaries was integrated into a single NHIS database since 2006. The NHIS database 
includes subjects’ demographics, utilization of inpatient and outpatient health care, pharmacy claims, data from 
health examination provided by the National Health Insurance Corporation, and mortality data for the entire 
Korean  population16. Detailed information the participants of national health examination is presented in the 
Supplementary Methods. Diagnoses were coded using the International Classification of Disease, Tenth, Clinical 
Modification (ICD-10-CM) codes. This study complied with the Declaration of Helsinki. This study was exempt 
from review by the institutional review board of Seoul National University Hospital (E-1612-036-812).
Study population. This study included the subjects who underwent the national health examination in 
2009 (n = 10,505,818). The exclusion criteria were as follows; (i) subjects aged under 20 years, (ii) subjects with 
missing health examination data, (iii) subjects with excessive alcohol intake (> 30 g/day), (iv) patients with obvi-
ous liver disease such as liver cirrhosis (ICD-10-CM codes, K703 and K76) and hepatitis (ICD-10-CM codes, 
B15-B19), (v) patients with prevalent cancer (ICD-10-CM codes, C00-96), and (vi) patients with prevalent AF 
(ICD-10-CM codes, I480-I484, I489) before 2009 (Fig. 1). Finally, a total of 8,048,055 subjects was included in 
the analysis (Fig. 1).
Definition of nonalcoholic fatty liver disease. In the previous studies, NAFLD was diagnosed 
using various methods such as ultrasonography, computed tomography, FLI, or circulating levels of liver 
 enzymes11–15,17–21. According to the definition of NAFLD, evidence of hepatic steatosis either on imaging or 
from the histology is  mandatory1. However, these methods involve high costs and are not usually feasible for 
the screening of fatty liver in a large population-based cohort. FLI is one of the alternative methods to diag-
nose NAFLD, and is a validated score using BMI, waist circumference, serum levels of γ-glutamyl transferase 
(GGT) and  triglyceride22,23. FLI < 30 rules out, while FLI ≥ 60 indicates fatty liver disease with good diagnostic 
 accuracy22,23. Therefore, we categorized subjects into 3 groups according to FLI as follows: FLI < 30, 30 ≤ FLI < 60, 
and FLI ≥ 60.
Covariates. The subjects’ demographic information including age, sex, socioeconomic status, comorbidi-
ties, the results of general health examination were collected. Comorbidities including hypertension, diabetes 
mellitus, and dyslipidemia were identified from the medical claim records with relevant ICD-10-CM codes and 
prescription records (Supplementary Table S1). Low income was defined as the lowest income at 25% among the 
entire Korean population. The general health examination included height, weight, waist circumference, systolic 
and diastolic blood pressure, and laboratory tests such as fasting glucose, total cholesterol, triglyceride, serum 
creatinine and liver enzymes (alanine transaminase [ALT], aspartate transaminase [AST], and GGT). Chronic 
kidney disease was defined as an estimated glomerular filtration rate of ≤ 60 mL/min/1.73  m2 calculated using 
the Modification of Diet in Renal Disease formula. Using the standardized self-reporting questionnaires, infor-
mation on smoking (never, ex-, and current smoker), alcohol consumption (non-drinker, and mild to moderate 
Figure 1.  Study enrollment flow. *Liver disease: obvious liver disease such as liver cirrhosis (ICD-10 codes, 
K703 and K76) and hepatitis (ICD-10 codes, B15–B19), (v) existing cancer (ICD-10 codes, C00-96).
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alcohol consumption defined as alcohol intake 0 to 30 g/day), and regular exercise were  obtained16. Regular 
exercise was defined as performing longer than 30 min of moderate physical activity 5 or more times per week or 
longer than 20 min of strenuous physical activity 3 or more times per week. BMI was calculated as weight in kilo-
grams divided by the square of height in meters (kg/m2). BMI was classified into 5 categories following World 
Health Organization recommendation for Asians: underweight, < 18.5 kg/m2; normal weight, 18.5–22.9 kg/m2; 
overweight, 23.0–24.9 kg/m2; obese class I, 25.0–29.9 kg/m2; and obese class II, ≥ 30.0 kg/m224,25.
Study outcome and follow‑up. The main study outcome was new-onset AF during follow-up. New-
onset AF was defined as at least 1 hospital visit with a diagnosis of AF according to the ICD-10-CM codes 
(I480-I484, I489) since the time of enrollment into the  study26. The cohort was followed up until the occurrence 
of incident AF, disqualification from the NHIS (death or immigration), or end of the study period (December 
31, 2017), whichever came first.
Statistical analysis. Baseline characteristics were described using percentage for categorical variables 
and mean ± standard deviation or median (interquartile ranges) for continuous variables. One-way analysis of 
variance for continuous variables and the chi-square test for categorical variables were used to evaluate the 
significance of differences among the groups stratified by FLI. The crude incidence rate (IR) of incident AF was 
calculated by dividing the number of AF cases by the total follow-up period (per 1000 person-years). Cox pro-
portional hazard regression models were used to evaluate the association between each variable and the occur-
rence of new-onset AF. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated.
Multivariable regression models were created and adjusted for age and sex (model 1); age, sex, hypertension, 
diabetes mellitus, dyslipidemia, chronic kidney disease, smoking status, alcohol consumption, regular exercise, 
and low income (model 2); model 3 was adjusted for the variables listed above, as well as for systolic blood pres-
sure, fasting glucose, and total cholesterol. HRs for AF incidence were estimated in subjects with 30 ≤ FLI < 60 
and FLI ≥ 60 and compared with subjects who had FLI < 30 as a reference group. Covariates for models 1 and 2 
were selected based on a priori knowledge of risk factors for AF, and model 3 included all variables in model 2 
plus the variables included in health examinations which have been well-established as risk factors of incident 
 AF27,28. The proportional hazards assumption for Cox models was graphically tested with a log minus log graph 
and verified with the Schoenfeld residuals. The results showed parallel log minus log survival curves and random 
patterns in Schoenfeld residuals, indicating no significant departure from proportionality assumption, and the 
tests were not statistically significant. Multi-collinearity was evaluated using the variance inflation factor (VIF). 
There was no substantial collinearity between the covariates (VIF = 1.38–1.78). To avoid the possible effect of 
multi-collinearity caused by correlation among BMI, waist circumference, GGT, and triglyceride, we did not 
include these variables in the multivariable Cox model.
We hypothesized that FLI might be a useful marker to estimate the metabolic status and the risk of AF in lean 
Asian subjects. To evaluate the impact of FLI on the risk of AF in different BMI groups, we performed a subgroup 
analysis in different BMI groups as an exploratory analysis. In this analysis, we performed multivariable Cox 
analysis using model 3, including age, sex, hypertension, diabetes, dyslipidemia, chronic kidney disease, smok-
ing, alcohol consumption, exercise, low income, systolic blood pressure, total cholesterol, and fasting glucose. 
Interactions between FLI and BMI relating to incident AF were calculated. Cumulative incidences of AF in the 
FLI groups within the different BMI groups were plotted using Kaplan–Meier analyses, and the long-rank test 
was performed to evaluate the differences between the groups.
p values < 0.05 were considered statistically significant. The Bonferroni significance was reported for multiple 
comparisons. A Bonferroni-correction significance level of p < 0.004 was used for 12 multiple tests (two FLI 
comparisons in all subjects and in each of five BMI categories) in model 3. Statistical analyses were performed 
using SAS version 9.4 (SAS Institute, Cary, North Carolina).
Results
Baseline characteristics. The mean FLI of the total study population was 26.0 ± 23.3. Among a total of 
8,048,055 subjects, 22.5% (n = 1,814,124) were categorized into the 30 ≤ FLI < 60 group, and 11.5% (n = 924,497) 
into the FLI ≥ 60 group. Baseline characteristics according to FLI ranges are presented in Table 1. A higher per-
centage of subjects with higher FLI value were men, and had comorbidities such as hypertension, diabetes mel-
litus, and dyslipidemia. In addition, subjects with higher FLI value had higher BMI, waist circumference, systolic 
and diastolic pressure, fasting glucose, total cholesterol, triglyceride, AST, ALT, and GGT, but lower HDL-C. A 
higher percentage of subjects with higher FLI value were current smokers, mild alcohol consumers and under-
took regular exercise; however, there was a lesser percentage of subjects with low income.
FLI and the risk of incident AF. During a median follow-up period of 8.3 years (interquartile ranges [IQR] 
8.1–8.6 years), 534,442 subjects were newly diagnosed with AF (IR, 8.27 per 1000 person-years). Supplementary 
Table S2 shows unadjusted HRs for incident AF for all independent variables. Higher age, female sex, as well as 
higher BMI, waist circumference, systolic and diastolic blood pressure, fasting glucose, total cholesterol, AST, 
ALT, GGT were associated with increased risk of incident AF. Hypertension, diabetes mellitus, dyslipidemia, and 
chronic kidney disease were also associated with an increased risk of AF.
The crude IRs of AF were 7.49, 9.95, and 9.48 per 1000 person-years in subjects with FLI < 30, 30 ≤ FLI < 60, 
and FLI ≥ 60, respectively (Table 2). On univariable analysis, HR of FLI as a continuous variable per units of 10 for 
the risk of AF was 1.061 (95% CI 1.060–1.062). Compared to subjects with FLI < 30, those with 30 ≤ FLI < 60, and 
FLI ≥ 60 showed a higher risk of incident AF (HR 1.328, 95% CI 1.320–1.337 and HR 1.267, 95% CI 1.257–1.278, 
respectively).
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After adjustment for age and sex, subjects with 30 ≤ FLI < 60 and FLI ≥ 60 showed a higher risk of incident 
AF (HR 1.097, 95% CI 1.090–1.104 and HR 1.188, 95% CI 1.178–1.198, respectively) than those with FLI < 30 
(Supplementary Table S2). The increased risk in subjects with 30 ≤ FLI < 60 and FLI ≥ 60 was 10% and 19%, 
respectively. Even when adjusted for the clinical variables in model 3, subjects with 30 ≤ FLI < 60 and FLI ≥ 60 
were independently and significantly associated with increased risks of AF by 5% and 12%, respectively (Table 2).
Exploratory subgroup analysis: FLI and the risk of incident AF according to different BMI 
ranges. In the total study population, 4% (n = 323,667) were classified as underweight, 40.5% (n = 3,257,976) 
as normal weight, 24.6% (n = 1,977,281) as overweight, 27.6% (n = 2,223,616) as obese class I, and 3.3% 
(n = 265,515) as obese class II. After dividing the subjects into 5 different BMI groups, In nonobese subjects 
(underweight, normal weight, and overweight groups, all groups with BMI < 25 kg/m2), crude IRs increased 
Table 1.  Baseline characteristics of study subjects stratified by fatty liver index. Categorical variables are 
presented as percentage and continuous variables are presented as mean ± standard deviation or median 
(interquartile ranges). ALT alanine transaminase, AST aspartate transaminase, BMI body mass index, BP 
blood pressure, CKD chronic kidney disease, eGFR estimated glomerular filtration rate, GGT gamma-glutamyl 
transferase, HDL high density lipoprotein.
Total (n = 8,048,055)
Fatty liver index group
0–30 (n = 5,309,434) 30–60 (n = 1,814,124)  ≥ 60 (n = 924,497)
Age 46.7 ± 14.1 45.4 ± 14.4 50.0 ± 13.5 47.3 ± 12.7
Men 52.0 40.9 69.5 81.6
Height (cm) 163.6 ± 9.2 162.3 ± 9.0 165.1 ± 9.4 167.6 ± 8.7
Weight (kg) 63.4 ± 11.5 58.6 ± 8.7 69.7 ± 8.8 78.6 ± 10.8
BMI (kg/m2) 23.6 ± 3.2 22.2 ± 2.4 25.5 ± 2.2 27.9 ± 3.0
Waist circumference (cm) 79.8 ± 9.1 75.5 ± 7.0 85.9 ± 5.4 92.1 ± 6.8
Systolic BP (mmHg) 122.0 ± 14.9 119.1 ± 14.3 126.5 ± 14.3 129.9 ± 14.5
Diastolic BP (mmHg) 76.0 ± 9.9 74.1 ± 9.5 78.8 ± 9.5 81.5 ± 9.9
Fasting glucose (mg/dL) 96.5 ± 22.1 93.2 ± 17.9 100.7 ± 25.1 106.7 ± 31.4
Total cholesterol (mg/dL) 195.2 ± 36.5 189.2 ± 34.4 204.0 ± 36.6 212.7 ± 38.8
Triglyceride (mg/dL) 108 (74–160) 87 (64–118) 154 (117–204) 226 (165–313)
GGT (mg/dL) 23 (16–37) 19 (14–25) 35 (25–50) 61 (40–97)
AST (mg/dL) 23 (19–28) 22 (19–26) 25 (21–30) 30 (24–38)
ALT (mg/dL) 20 (15–29) 18 (14–23) 26 (20–36) 37 (27–53)
Hypertension 24.1 17.1 34.9 43.3
Diabetes mellitus 7.9 4.7 12.0 17.8
Dyslipidemia 17.6 12.1 25.2 33.9
CKD (eGFR ≤ 60 mL/min/1.73  m2) 5.8 5.3 6.9 6.3
Smoking status
Non-smoker 62.3 70.5 50.2 38.6
Ex-smoker 13.3 10.3 18.6 19.9
Current smoker 24.5 19.2 31.2 41.6
Alcohol consumption
Non-drinker 54.2 59.0 48.6 37.4
Mild (0–30 g/day) 45.8 41.0 51.4 62.6
Regular exercise 51.0 49.9 52.6 54.2
Low income 27.0 28.7 24.1 23.4
Table 2.  Hazard ratios of the fatty liver index for incident atrial fibrillation. Model 1: age sex. Model 2: Model 
1 + hypertension, diabetes, dyslipidemia, chronic kidney disease, smoking, alcohol consumption, exercise, low 
income. Model 3: Model 2 + systolic blood pressure, total cholesterol, fasting glucose. AF atrial fibrillation, 
FLI fatty liver index, IR incidence rate. *IR, incidence rate (per 1000 person-years). a Bonferroni-corrected 
significance level of p < 0.004 was used for multiple comparisons.
FLI group Total number AF cases IR* Model 1 Model 2 Model 3
0–30 5,309,434 320,433 7.49 1 (reference) 1 (reference) 1 (reference)
30–60 1,814,124 144,052 9.95 1.097 (1.090–1.104) 1.038 (1.031–1.045) 1.053 (1.046–1.060)a
 ≥ 60 924,497 69,957 9.48 1.188 (1.178–1.198) 1.090 (1.080–1.100) 1.115 (1.106–1.125)a
5
Vol.:(0123456789)
Scientific Reports |         (2021) 11:3737  | https://doi.org/10.1038/s41598-021-83367-x
www.nature.com/scientificreports/
with increasing FLI, and this dose–response relationship was more significant in underweight subjects (Supple-
mentary Table S3). Obese subjects (BMI ≥ 25 kg/m2) did not show an association between FLI and the risk of AF.
Cumulative crude incidence of AF was significantly associated with increasing FLI in underweight, normal 
weight, and overweight groups (Fig. 2). Although log-rank p values were also significant in obese class I and II 
groups due to the large sample size, the incidence of AF was less impacted by the increase in FLI and a linear 
dose–response relationship was not observed. After adjustment for the clinical variables (model 3), we found 
that high FLI (30 ≤ FLI < 60 and FLI ≥ 60) dramatically increased the risk of incident AF in underweight sub-
jects (Fig. 3, Supplementary Table S3). In underweight subjects, FLI between 30 and 60 was associated with a 
1.6 times increase in incident AF while FLI ≥ 60 increased the risk of AF risk by 2 times compared with that of 
FLI < 30. In normal weight and overweight subjects, high FLI was also significantly associated with increased 
risk of incident AF, but the HRs were attenuated. For subjects with obesity class I and II, high FLI did not have 
any significant effect on the risk of incident AF, except for a modest effect of FLI ≥ 60 in obese class I subjects 
(Fig. 3, Supplementary Table S3).
Discussion
To our knowledge, this is the largest cohort study examining the association between NAFLD assessed by FLI 
and incident AF, especially in the Asian population. We have demonstrated the following principal outcomes: (i) 
among the entire Korean adult population who underwent health examination provided by the government in 
2009, NAFLD was common; 22.5% were categorized as 30 ≤ FL I < 60 and 11.5% had FLI ≥ 60; (ii) subjects with 
30 ≤ FLI < 60 and FLI ≥ 60 were associated with an increased risk of AF by 5% and 12%, respectively; (iii) when 
stratified according to BMI, high FLI (30 ≤ FLI < 60 and FLI ≥ 60) dramatically increased the risk of incident 
AF, especially in underweight subjects; however, this was attenuated in normal weight and overweight subjects; 
and (iv) in subjects with obesity class I and II, high FLI did not have any significant association with the risk of 
incident AF, except for a modest effect of FLI ≥ 60 in obese class I subjects.
AF is the most common cause of sustained cardiac arrhythmia, and is associated with increased risks of 
stroke, heart failure, and  mortality29. The association between the incidence of AF and metabolic syndrome is 
well  known30,31. NAFLD frequently coexists with the components of metabolic syndrome, hence the impact of 
NAFLD on the risk AF risk has drawn attention.
However, only limited data related to NAFLD and the risk of AF has been published, with conflicting 
 results6–9. A recent meta-analysis analyzed 5 previous studies reporting the association between NAFLD and 
prevalence of  AF9. NAFLD was diagnosed using various modalities like ultrasonography, computed tomography, 
Figure 2.  Cumulative incidence curves of AF stratified by fatty liver index in different BMI groups: 
underweight (BMI < 18.5 kg/m2), normal weight (BMI 18.5–23 kg/m2), overweight (BMI 23–25 kg/m2), obese I 
(BMI 25–30 kg/m2), and obese II (BMI ≥ 30 kg/m2). AF atrial fibrillation, BMI body mass index, FLI fatty liver 
index.
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or diagnostic codes. In a pooled analysis, NAFLD was associated with a higher prevalence of AF (odds ratio 2.07, 
95% CI 1.38–3.10); however, there were only 3 original papers evaluating the association between NAFLD and 
incidence of AF in longitudinal  cohorts6–8.
Targher et al. included subjects with type 2 diabetes (Italian; total 400 subjects, 281 subjects with NAFLD 
assessed by ultrasonography)6, and 2 other studies included middle-aged subjects; from Finland (total 958 sub-
jects, 249 subjects with NAFLD assessed by ultrasonography)7, and from United States (total 2060 subjects, 424 
subjects with NAFLD assessed by computed tomography)8. In a pooled analysis, NAFLD was not significantly 
associated with an increased risk of incident AF in the overall study population (HR 1.34, 95% CI 0.92–1.95)9. 
In fact, NAFLD had an increased risk of incident AF only in diabetic patients (HR 4.96, 1.42–17.28)6,9. Although 
NAFLD was diagnosed using different imaging modalities in these previous studies, there might be some limita-
tions when comparing these results with our present study. Of note, we found no comprehensive large popula-
tion-based longitudinal cohort data from these previous studies. Notably, there were no data about Asian subjects.
Furthermore, despite NAFLD commonly coexisting with obesity, nonobese NAFLD is common in  Asians11–15. 
Although FLI has no or only a modest impact on the risk of incident AF in the general population, we hypoth-
esized that there might be a significant interaction between the effect of FLI on the risk of AF, based on different 
BMI  categories32. We found that subjects with 30 ≤ FLI < 60 and FLI ≥ 60 were associated with increased risks 
of AF by 5% and 12% respectively, in the overall study population. However, we have demonstrated for the first 
time a significant association between BMI and the impact of FLI on incident AF. In subjects with lower BMI, 
high FLI was more strongly associated with an increased risk of incident AF. Compared to the normal weight 
with normal FLI group, underweight subjects with FLI ≥ 60 showed a 2.1 times increase in the risk of incident 
AF (Supplementary Table S4). Obese subjects showed an increased risk of incident AF compared to the normal 
weight with normal FLI group, and FLI did not have an additional impact on the risk of incident AF among 
obese subjects (Supplementary Table S4).
NAFLD could be found in nonobese (BMI < 25 kg/m2) and lean (BMI < 23 kg/m2) subjects; more impor-
tantly, NAFLD appears to be more frequent in the Asian  population11–15. The histology of nonobese NAFLD 
does not differ from that of obese NAFLD. In a recent report, lean NAFLD had a lower degree of steatosis and 
less advanced fibrosis but more severe lobular inflammation compared to obese  NAFLD33. Indeed, nonobese 
Figure 3.  Hazard ratios of the FLI for incident AF in different BMI groups. *Adjusted HR: Model 3 (age, sex, 
hypertension, diabetes, dyslipidemia, chronic kidney disease, smoking, alcohol consumption, exercise, low 
income, systolic blood pressure, total cholesterol, and fasting glucose). AF atrial fibrillation, BMI body mass 
index, CI confidence interval, FLI fatty liver index, HR hazard ratio.
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NAFLD is a similar spectrum to the “metabolically obese normal weight (MONW)” that shows insulin resist-
ance with normal weight.
BMI represents general obesity but sometimes fails to reflect body fat distribution. In contrast, visceral 
abdominal adiposity is associated with metabolic syndrome and is a key link to  NAFLD15. Of note, Asian non-
obese NAFLD patients have a higher body fat content and evidence of visceral adiposity than subjects with a 
comparable BMI without  NAFLD11. Furthermore, the association with metabolic syndrome components was 
stronger in nonobese NAFLD than in obese  NAFLD34.
In the present study, when dividing the subjects according to the BMI, the associations between FLI and the 
risk of AF was accentuated in nonobese groups (underweight and normal BMI groups). We can assume that 
triglyceride and GGT among four components of FLI might be the main parameters reflecting subjects’ metabolic 
healthiness in nonobese subjects. Triglyceride is one of the components to diagnose the metabolic  syndrome35, 
and GGT is a well-known parameter that is independently associated with the development of obesity, hyperten-
sion and insulin resistance, which are components of metabolic  syndrome36–38. In a previous study, we found a 
close association between GGT and the AF risk; although the obese group generally showed higher AF incidence 
than the nonobese group, the association between GGT and the AF risk was more accentuated in the nonobese 
 population32. Nonobese NAFLD subjects generally have a higher prevalence of the components of metabolic 
syndrome, including high TG, high blood pressure, insulin resistance such as impaired fasting glucose, and 
overt  diabetes34,39. Thus, it would be important to identify high-risk nonobese NAFLD patients and correct their 
metabolic profile by reducing visceral fat through dietary changes and regular physical activity.
There is also a paucity of data about the long-term prognosis of nonobese NAFLD patients. In a recent study, 
lean NAFLD subjects had a higher overall and cardiovascular mortality than the obese NAFLD subjects, but 
such data are still  controversial33,40. Our study clearly shows an increased risk of incident AF in nonobese and 
lean NAFLD patients. Further studies on cardiovascular clinical outcomes in nonobese NAFLD subjects are 
warranted.
Study limitations. Several limitations should be considered in this study. First, although we used the 
Korean NHIS database, which included the entire Korean population and a large number of patients received 
the national health examinations (66.0% in 2009)41, there is still a possibility of selection bias that the present 
analysis was performed in subjects who actually underwent the national health examination. Second, incident 
AF was identified using diagnostic codes in the claims database, which might result in misclassification due to 
both, underestimation and overestimation of AF. To avoid misclassification, we used the validated definitions 
from a previous study using the Korean NHIS  database26. However, there is still a possibility that undetected AF 
patients with asymptomatic AF who were not treated by any medical service could exist. Third, using FLI as a 
surrogate measure for NAFLD could be a limitation of our study. In this large population-based study, the results 
of ultrasound, computed tomography, magnetic resonance imaging, or liver biopsy were not available to evaluate 
NAFLD. In addition, the diagnostic accuracy of each study is different, and the diagnostic ability of these tools 
varies depending on the sample  population2. For example, Bedogni et al. developed FLI based on the diagnosis 
of the fatty liver using ultrasound, and FLI provided good diagnostic accuracy for fatty liver in the original 
study population (area under the receiver operating characteristics [AUROC] = 0.85, 95% CI 0.81–0.88)22. The 
characteristics of the study population in the previous study (mean age 57 years, 61.5% men, and mean BMI 
27 kg/m2) were slightly different from those of our study population. Nonetheless, external validation of FLI in 
other populations showed comparable diagnostic accuracy for  NAFLD42. Koehler et al.42 reported the external 
validation of FLI collecting ultrasonography in the Rotterdam Study (2652 subjects). NAFLD was present in 925 
(34.9%) of participants, and the median FLI was 42.2 (interquartile ranges 22.6–67.3). Applying cutoffs proposed 
by Bedogni et al.22, 926 participants (34.9%) had FLI < 30, and 864 participants (32.6%) had FLI ≥ 60. AUROC of 
FLI for predicting NAFLD was 0.813 (95% CI 0.797–0.830). Sensitivity and specificity of FLI < 30 for predicting 
the absence of NAFLD were 91.5% and 49.0%, respectively. The sensitivity and specificity of FLI ≥ 60 for predict-
ing the presence of NAFLD were 60.4% and 92.3%, respectively. Also, several previous studies tried to validate 
the FLI using ultrasonography, including in the Asian  population43–47. Given that the results of imaging studies 
for diagnosing NAFLD could not be obtained in the present study, we could not perform further validation of 
FLI for diagnosing NAFLD in our dataset, which remains our major limitation. Fourth, although we assessed 
all the available covariates and included a multivariable analysis for adjusting the potential confounding fac-
tors of incident AF, some unmeasurable residual confounding factors that might be not accessible in the NHIS 
database could exist. Moreover, we did not assess longitudinal changes in the metabolic status of either FLI or its 
components (such as waist circumference, BMI, triglyceride and GGT levels or treatment) on NAFLD or other 
chronic diseases during the follow-up period. These might be confounding factors that could affect the incidence 
of AF. Fifth, variables such as smoking status, alcohol consumption, and exercise were assessed by self-reported 
questionnaires, including the national health examination. Although these variables from the Korean NHIS 
database have been widely used in many previous  studies48–50, there might be a possibility of inaccuracy or recall 
bias in this information. Lastly, since this is a retrospective observational cohort study, our findings suggest an 
association between the presence of NAFLD as assessed by FLI with incident AF, but this does not indicate a 
causal relationship.
Conclusions
In this large-scale Asian population, NAFLD assessed by FLI was independently associated with a higher 
risk of incident AF. The impact of NAFLD on AF risk might be accentuated in lean subjects with low weight 
(BMI < 18.5 kg/m2) and in those with normal weight (BMI 18.5–22.9 kg/m2).
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